Oren Hershkovitz
Directeur Général chez ENLIVEX THERAPEUTICS LTD.
Fortune : 27 778 $ au 30/04/2024
Postes actifs de Oren Hershkovitz
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ENLIVEX THERAPEUTICS LTD. | Directeur Général | 16/11/2019 | - |
OPKO Biologics Ltd.
 OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Directeur/Membre du Conseil | 01/09/2016 | - |
Historique de carrière de Oren Hershkovitz
Formation de Oren Hershkovitz
| Ben-Gurion University of the Negev | Doctorate Degree |
Statistiques
Internationale
| Israël | 4 |
Opérationnelle
| Chief Executive Officer | 1 |
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENLIVEX THERAPEUTICS LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Health Technology |
- Bourse
- Insiders
- Oren Hershkovitz
- Expérience
